Recommendation of the President – Kalydeco (ivacaftor)

On 4 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 120/2024 on the evaluation of the drug Kalydeco (ivacaftor) used in combination with Kaftrio (ivacaftor + tezacaftor +elexacaftor) under the drug program “Treatment of patients with cystic fibrosis (ICD-10: E84)”

Publication in Public Information Bulletin (BIP) >>